Trilaciclib

Overview

Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC 50 values of 1 nM and 4 nM for CDK4 and CDK6 , respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU ( HY-90006 ) chemotherapy.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-101467
• CAS No.: 1374743-00-6
• Molecular Formula: C24H30N8O
• Molecular Weight: 446.55
• Purity: 99.42%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 10 mg/mL (22.39 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source